A case report of vaccine-induced immune thrombocytopenia and thrombosis syndrome after Ad26.COV2.S vaccine (Janssen/Johnson & Johnson)

France, Castan et al, January 2022, Therapie Summary On August 2, 2021, ten days after receiving a dose of Ad26.COV2.S vaccine (Janssen/Johnson & Johnson), a 57-years-old man was admitted for left hemiplegia. The rest of clinical examination was unremarkable. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR) testing by nasopharyngeal swab was … Continue reading A case report of vaccine-induced immune thrombocytopenia and thrombosis syndrome after Ad26.COV2.S vaccine (Janssen/Johnson & Johnson)

COVID-19 Vaccine-Associated Thrombosis With Thrombocytopenia Syndrome (TTS): A Systematic Review and Post Hoc Analysis

Pakistan, 7 September 2021, Hafeez et al, Clinical and Applied Thrombosis/Hemostasis Summary We utilized the World Health Organization’s criteria for a confirmed and probable case of TTS following COVID-19 vaccination and conducted a systematic review and posthoc analysis using the PRISMA 2020 statement. Of the 175 studies identified, a total of 25 studies with 69 … Continue reading COVID-19 Vaccine-Associated Thrombosis With Thrombocytopenia Syndrome (TTS): A Systematic Review and Post Hoc Analysis

Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia

28 September 2021, van Kammen et al, JAMA Neurology Summary This cohort study used data from an international registry of consecutive patients with CVST within 28 days of SARS-CoV-2 vaccination included between March 29 and June 18, 2021, from 81 hospitals in 19 countries. For reference, data from patients with CVST between 2015 and 2018 … Continue reading Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia

Pulmonary embolism, transient ischaemic attack and thrombocytopenia after the Johnson & Johnson COVID-19 vaccine

U.S, 25 June 2021, Malik et al, BMJ Case Reports Summary We present the case of a 43-year-old woman with a history of dyslipidaemia, depression, gastro-oesophageal reflux disease and obesity presenting with dyspnoea, headache and light headedness of 3 days’ duration. Ten days prior, she had received the J&J COVID-19 vaccine. She was found to have … Continue reading Pulmonary embolism, transient ischaemic attack and thrombocytopenia after the Johnson & Johnson COVID-19 vaccine

Deep Venous Thrombosis after Ad26.COV2.S Vaccination in Adult Male

U.S, 14 October 2021, Hussain et al, Case Reports in Critical Care Summary A 21-year-old male without significant past medical history presented to the emergency department 8 days after receiving the Ad26.COV2.S vaccine, with complaints of left groin pain and inability to bear weight on the left leg. On initial evaluation, he was noted to … Continue reading Deep Venous Thrombosis after Ad26.COV2.S Vaccination in Adult Male

Diagnosis and Management of Cerebral Venous Sinus Thrombosis With Vaccine-Induced Immune Thrombotic Thrombocytopenia

July 2021, Stroke Summary Recent reports from the Centers of Disease Control and the US Food and Drug Administration identified 6 cases of CVST associated with thrombocytopenia in US patients who had received the Ad26.COV2.S (Janssen) coronavirus disease 2019 (COVID-19) vaccine. Similar thromboembolic events were reported in Europe following ChAdOx1 nCoV-19 (AstraZeneca) vaccination. Both the … Continue reading Diagnosis and Management of Cerebral Venous Sinus Thrombosis With Vaccine-Induced Immune Thrombotic Thrombocytopenia

Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far?

U.S, 18 July 2021, Das et al, Children Summary A cross-sectional study of 29 published cases of acute myopericarditis following COVID-19 mRNA vaccination. The most common presentation was chest pain within 1–5 days after the second dose of mRNA COVID-19 vaccination. All patients had an elevated troponin. Cardiac magnetic resonance imaging revealed late gadolinium enhancement … Continue reading Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far?

Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination

Austria, 27 August 2021, Gelbenegger et al, Vaccines Summary We report the case of a 19-year-old male who complained of myalgia, muscle weakness, and darkened urine two days after receiving his Ad26.COV2.S (Johnson & Johnson, New Brunswick, New Jersey, United States) COVID-19 vaccination. Blood examination revealed an increased creatine kinase (CK) level, and his urinary … Continue reading Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination

Temporal association between the COVID-19 Ad26.COV2.S vaccine and acute myocarditis: A case report and literature review

U.S 9 August 2021, Sulemankhil et al, Cardiovascular Revascularization Medicine Summary Out of 38 articles, 23 case reports and case series were selected for further analysis. These articles included 81 patients with 77 males who were primarily under the age of 30. Onset of myocarditis was noted in 71 individuals following their second mRNA COVID-19 vaccine; nine … Continue reading Temporal association between the COVID-19 Ad26.COV2.S vaccine and acute myocarditis: A case report and literature review

Thrombotic Thrombocytopenic Purpura after Ad26.COV2-S Vaccination

U.S, 25 May 2021, Yocum et al, American Journal of Emergency Medicine Summary We report a 62-year-old female who presented to the emergency department (ED) with acute onset of altered mental status. She had received the Ad26.COV2-S vaccine 37 days prior to ED presentation. She developed thrombotic thrombocytopenic purpura (TTP) and no other cause was … Continue reading Thrombotic Thrombocytopenic Purpura after Ad26.COV2-S Vaccination

Thrombocytopenia and splanchnic thrombosis after Ad26.COV2.S vaccination successfully treated with transjugular intrahepatic portosystemic shunting and thrombectomy

U.S, 31 May 2021, Dhoot et al, American Journal of Haematology Summary Our patient, a 24-year-old previously healthy male, presented with 10-day history of severe abdominal pain, nausea, vomiting, and decreased oral intake. He had been seen at urgent care 2 days earlier for similar symptoms, treated for presumed gastritis with belladonna alkaloids, phenobarbital, antacid, and … Continue reading Thrombocytopenia and splanchnic thrombosis after Ad26.COV2.S vaccination successfully treated with transjugular intrahepatic portosystemic shunting and thrombectomy

Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines

15 June 2021, Journal of Autoimmunity Summary Cerebral venous thrombosis (CVT) events have been reported after vaccination with adenoviral COVID-19 vector vaccines. This study aimed to compare the clinical presentations and courses of vaccine-induced thrombotic thrombocytopenia (VITT) between the two adenoviral vector vaccines, Ad26.COV.2.S (Janssen/Johnson &Johnson) and ChAdOx1 nCoV-19 (Astra-Zeneca). We found that CVT after … Continue reading Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines

Coronavirus vaccine – weekly summary of Yellow Card reporting (Updated 26 November 2021)

Summary Thrombo-embolic (blood clotting) events with concurrent low platelets Up to 17 November 2021, the MHRA had received Yellow Card reports of 426 cases of major thromboembolic events (blood clots) with concurrent thrombocytopenia (low platelet counts) in the UK following vaccination with COVID-19 Vaccine AstraZeneca. Forty-seven of the 426 reports have been reported after a second dose. … Continue reading Coronavirus vaccine – weekly summary of Yellow Card reporting (Updated 26 November 2021)

Neurological side effects of SARS-CoV-2 vaccinations

Austria, 31 October 2021, Acta Neurologica Scandinavia Summary Literature review of neurological side effects of SARS-CoV-2 vaccines. They include headache, GuillainBarre syndrome (GBS), venous sinus thrombosis (VST), transverse myelitis, facial nerve palsy, small fiber neuropathy, newly developing multiple sclerosis. By far the most frequent of the neurological adverse reactions to SARS-CoV-2 vaccinations is headache, followedby … Continue reading Neurological side effects of SARS-CoV-2 vaccinations

A review of COVID-19 vaccination and the reported cardiac manifestations

Singapore, 19 November 2021, Singapore Medical Journal Summary The main reported cardiac side effects associated with COVID-19 vaccines were myocarditis and pericarditis, with a few reports of AMI, arrhythmia and stress cardiomyopathy.Myocarditis and pericarditis were the most common reported post-mRNA vaccine cardiac events particularly in young adolescent males and after the second dose of vaccination. … Continue reading A review of COVID-19 vaccination and the reported cardiac manifestations

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination

U.S, 20 May 2021, Muir et al New England Journal of Medicine Summary A 48-year-old White woman with an unremarkable medical history presented to the emergency department with a 3-day history of malaise and abdominal pain. The initial evaluation at another hospital showed mild anemia and severe thrombocytopenia (platelet count, 13,000 per cubic millimeter [reference … Continue reading Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination

Early Outcomes of Bivalirudin Therapy for Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After Ad26.COV2.S Vaccination

U.S, October 2021, Annals of Emergency Medicine Summary A 40-year-old Caucasian woman was found to have thrombocytopenia, cerebral venous sinus thrombosis, and pulmonary embolism following vaccination for COVID-19 with Ad26.COV2.S. She exhibited a steady rise in platelet count: 20×109/L at hospital day 0, 115×109/L at discharge on hospital day 6, and 182×109/L on outpatient follow-up … Continue reading Early Outcomes of Bivalirudin Therapy for Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After Ad26.COV2.S Vaccination